Disposition of anticonvulsants in childhood
- PMID: 2692942
- DOI: 10.2165/00003088-198900171-00007
Disposition of anticonvulsants in childhood
Abstract
There have been great advances in our understanding of the childhood epilepsies within recent years and at the same time there has been increasing awareness of the pharmacokinetic properties of the anticonvulsant drugs. It has been increasingly recognised that pharmacokinetic parameters of anticonvulsants are not constant, but are subject to influences by a number of physiological variables over which age is a major determinant. As changes in pharmacokinetic parameters will alter dosage requirements, dosage regimens cannot be transferred from one age group to another without the risk of underdosing or overdosing. Drug monitoring techniques are being increasingly used as a guide to correct dosing but knowledge of the limitations of monitoring is as important as knowledge of potential benefits for monitoring to be used correctly. An overview of the important pharmacokinetic properties of anticonvulsant drugs is provided, with emphasis on findings in children where such data are available.
Similar articles
-
Pharmacokinetic optimisation of anticonvulsant therapy.Clin Pharmacokinet. 1992 Sep;23(3):216-30. doi: 10.2165/00003088-199223030-00004. Clin Pharmacokinet. 1992. PMID: 1511537 Review.
-
Plasma level monitoring of anticonvulsants.Clin Pharmacokinet. 1976;1(1):52-66. doi: 10.2165/00003088-197601010-00005. Clin Pharmacokinet. 1976. PMID: 797492 Review.
-
Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age.Epilepsia. 2010 Oct;51(10):1954-62. doi: 10.1111/j.1528-1167.2010.02598.x. Epub 2010 Sep 29. Epilepsia. 2010. PMID: 20880232
-
[The pharmacokinetic optimization of depakin in children with epilepsy].Zh Nevrol Psikhiatr Im S S Korsakova. 1994;94(6):37-8. Zh Nevrol Psikhiatr Im S S Korsakova. 1994. PMID: 7740873 Russian.
-
Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.Clin Pharmacokinet. 2006;45(11):1077-97. doi: 10.2165/00003088-200645110-00003. Clin Pharmacokinet. 2006. PMID: 17048973 Review.
Cited by
-
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.Br J Clin Pharmacol. 1998 Jun;45(6):525-38. doi: 10.1046/j.1365-2125.1998.00721.x. Br J Clin Pharmacol. 1998. PMID: 9663807 Free PMC article. Review.
-
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.Clin Pharmacokinet. 1995 Oct;29(4):257-86. doi: 10.2165/00003088-199529040-00005. Clin Pharmacokinet. 1995. PMID: 8549027 Review.
-
Therapeutic drug monitoring of phenytoin. Rationale and current status.Clin Pharmacokinet. 1990 Nov;19(5):341-58. doi: 10.2165/00003088-199019050-00001. Clin Pharmacokinet. 1990. PMID: 2268985 Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials